Skip to main content
AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.78%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B0.00%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA-0.02%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%HD+0.05%3988.HK-1.13%BAC+0.05%1816.HK+3.45%GE-0.03%0857.HK-0.49%ORCL-0.01%UNH+0.01%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.02%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.22%ETHUSD+71.01%USDTUSD+0.12%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.20%ZECUSDT+2.26%XMRUSDT-0.11%DOGEUSD+69.80%LINKUSD+2.87%XLMUSD-0.66%BCHUSDT-0.65%LTCUSD+68.40%UNIUSD-0.38%TONUSD+79.92%SUIUSD+1.76%HBARUSDT+0.13%TAOUSDT+2.25%AAVEUSD+1.48%ONDOUSDT+1.12%DOTUSDT+1.61%ICPUSDT+2.94%WLDUSDT+3.76%ARBUSDT+2.09%ATOMUSDT-0.07%INJUSDT+4.12%STXUSDT+2.99%PYTHUSDT+4.63%TIAUSDT+3.05%FETUSDT+0.01%SEIUSDT+0.59%JUPUSDT+3.25%GRTUSDT+0.76%OPUSDT+1.55%IOTAUSDT+2.04%POLUSDT+0.60%WIFUSDT+1.51%AXSUSDT+0.09%EOSUSDT+0.60%IMXUSDT+0.09%FARTCOINUSDT+1.18%GALAUSDT+3.50%DYDXUSDT+0.13%ORDIUSDT+2.66%NOTUSDT+1.19%RONINUSDT+1.91%AAPL+0.69%MSFT+0.96%GOOGL+1.78%NVDA+3.63%AMZN+1.69%SPCX+1.42%TSM+2.78%AVGO+2.47%META+1.21%TSLA+1.46%LLY+0.01%WMT+0.08%JPM-0.04%BRK-B0.00%V+0.01%SKHY0.00%AMD+3.30%MU+2.48%XOM0.00%JNJ+0.15%MA-0.02%ABBV+0.08%ASMLa-9.33%COST+0.19%1398.HK+0.25%KO+0.03%CVX+0.03%0700.HK-1.26%PG+0.09%CSCO+0.07%0939.HK0.00%HD+0.05%3988.HK-1.13%BAC+0.05%1816.HK+3.45%GE-0.03%0857.HK-0.49%ORCL-0.01%UNH+0.01%1288.HK-0.45%PM+0.02%0005.HK-3.08%NVS-0.01%HSBA.L-3.62%INTC+3.30%AZN-0.01%MS+0.02%RTX+0.02%ORp-0.36%TMO+0.14%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDILS+0.16%USDCOP-0.04%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURNZD0.00%AUDCHF0.00%EURSEK0.00%GBPUSD0.00%GBPCHF0.00%USDDKK0.00%USDHKD0.00%GBPCAD0.00%NZDCAD0.00%GBPNZD0.00%GBPAUD0.00%EURCAD0.00%EURJPY0.00%EURNOK0.00%EURUSD0.00%CADCHF0.00%CADJPY0.00%CHFJPY0.00%NZDCHF0.00%NZDSGD0.00%EURCZK0.00%NOKJPY0.00%AUDCAD0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%NZDUSD0.00%GBPJPY0.00%EURGBP0.00%AUDNZD0.00%AUDJPY0.00%AUDUSD0.00%USDJPY0.00%USDCNH0.00%EURCHF0.00%USDMXN0.00%USDNOK0.00%USDTHB0.00%USDTRY0.00%USDSEK0.00%USDCAD0.00%USDCHF0.00%EURHKD0.00%EURAUD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%EURPLN0.00%NZDJPY0.00%CHFNOK0.00%EURDKK0.00%NZDMXN0.00%GBPSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+1.22%ETHUSD+71.01%USDTUSD+0.12%XRPUSD+61.26%SOLUSD+68.72%TRXUSDT+0.20%ZECUSDT+2.26%XMRUSDT-0.11%DOGEUSD+69.80%LINKUSD+2.87%XLMUSD-0.66%BCHUSDT-0.65%LTCUSD+68.40%UNIUSD-0.38%TONUSD+79.92%SUIUSD+1.76%HBARUSDT+0.13%TAOUSDT+2.25%AAVEUSD+1.48%ONDOUSDT+1.12%DOTUSDT+1.61%ICPUSDT+2.94%WLDUSDT+3.76%ARBUSDT+2.09%ATOMUSDT-0.07%INJUSDT+4.12%STXUSDT+2.99%PYTHUSDT+4.63%TIAUSDT+3.05%FETUSDT+0.01%SEIUSDT+0.59%JUPUSDT+3.25%GRTUSDT+0.76%OPUSDT+1.55%IOTAUSDT+2.04%POLUSDT+0.60%WIFUSDT+1.51%AXSUSDT+0.09%EOSUSDT+0.60%IMXUSDT+0.09%FARTCOINUSDT+1.18%GALAUSDT+3.50%DYDXUSDT+0.13%ORDIUSDT+2.66%NOTUSDT+1.19%RONINUSDT+1.91%
ST

Spyre Therapeutics, Inc. (SYRE)

NASDAQ • Healthcare

$93.47
-$4.15 (-4.3%)
Market open

Last close at November 20, 2026 at 21:00 UTC

Open$95.93
Previous Close$93.47
Day Range$93.22 - $99.56
Avg. Volume (3M)962.4K
Market Cap$8.8B
52 Week Range
$24.58$110.64
Next EarningsIn 88 daysFeb 18, 2027

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$90.4M
Net Income (TTM)
-$263.8M
EPS (TTM)
-$2.74
ROA (TTM)
-23.99%
Current Ratio
27.4

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-12.1%Q2 2026-$0.74
+52.6%Q3 2026-$0.36
-14.3%Q4 2026-$0.94
Next

Feb 18

in 88 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -14.3%

Spyre Therapeutics’ loss widened sharply in the third fiscal quarter of 2026, and EPS of -$0.94 trailed the -$0.79 estimate by -$0.15, based on preliminary results reported November 3, 2026. Net income was a loss of about $96.1 million, down -759.5% year over year from a loss of about $11.2 million a year ago, alongside an operating loss of roughly $105.7 million. EPS also deteriorated -526.7% year over year from -$0.15. Cash use remained elevated, with negative operating cash flow of about $77.5 million. Consensus for the next period calls for EPS of -$0.87.

View full earnings history

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a preclinical Biotechnology company listed on the NASDAQ Capital Market as SYRE that develops treatments for inflammatory bowel disease. The company focuses on drug candidates for people with ulcerative colitis and Crohn's disease, placing it in the biotech side of the healthcare sector.

Name
Spyre Therapeutics, Inc.
CEO
Cameron Turtle
Industry
Healthcare
Year Founded
2013
Employees
125

Today's Snapshot

AI-generated

SYRE closed 4.2% below yesterday's close, while its sector was flat.

Trading Volume

Below 10d avg (973.1K)

770.4K

vs S&P 500 Today

Underperforming Market

-0.67%

Updated: November 20, 2026 at 21:11 UTC

Technical Indicators

2 Buy3 Neutral3 Sell
SYRE displays a neutral posture with mixed signals: trend strength is weak with ADX in the mid-teens, momentum indicators hover around neutral with RSI near the mid-40s and a modest MACD, and short-term averages sit above the current price while longer-term averages remain supportive. Volatility is moderate and On-Balance Volume shows more selling than buying, while the pivot around 99.5 marks resistance above the market. These factors combine to a balanced technical picture without a clear directional bias. Technical takeaway: Neutral.
All signals
  • EMA (5 indicators)$74.85 - $98.79
    Sell
  • RSI (14)46.18
    Neutral
  • Stochastic %K (14, 3, 3)26.58
    Neutral
  • MACD Level (12, 26)1.70
    Neutral

Peers & Related Assets

ANABAnaptysBio, Inc.
$46.63-1.6%
ARDXArdelyx, Inc.
$2.99-2.3%
UPBUpstream Bio, Inc.
$1.59-20.5%
ABVXAbivax S.A.
ODTXOdyssey Therapeutics, Inc.
ACRSAclaris Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.